These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18310826)

  • 1. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drugs under development for osteoporosis ].
    Masuda H; Tanaka S
    Nihon Rinsho; 2009 May; 67(5):980-4. PubMed ID: 19432120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].
    Endo I; Matsumoto T
    Clin Calcium; 2010 May; 20(5):700-8. PubMed ID: 20445281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-forming agents in the management of osteoporosis.
    Neuprez A; Reginster JY
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate improves bone microarchitecture in osteoporosis.
    Hamdy NA
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv9-13. PubMed ID: 19783592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium as therapy for osteoporosis.
    Marie PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strontium ranelate's (Osseor) dual mode of action: increasing bone mass and decreasing bone resorption].
    Kaliterna DM
    Reumatizam; 2008; 55(2):73-4. PubMed ID: 19024281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].
    Korsić M; Giljević Z; Kastelan D
    Lijec Vjesn; 2006; 128(5-6):180-2. PubMed ID: 16910420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone].
    Kobayashi T
    Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trends in osteoporosis].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2008 Jan; 4(140):144-6, 148-9. PubMed ID: 18309878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. About the comparison of two anabolic agents, teriparatide and strontium ranelate, in treated osteoporotic women.
    Meunier PJ; Boivin G; Marie PJ
    J Bone Miner Res; 2009 Dec; 24(12):2066; author reply 2067-8. PubMed ID: 19839763
    [No Abstract]   [Full Text] [Related]  

  • 20. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.